Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Admelog Insulin lispro Cancelled
Cyramza Ramucirumab Cancelled
Opdivo nivolumab Gastroesophageal junction or esophageal adenocarcinoma Pending
Keytruda Pembrolizumab
Viibryd vilazodone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Lynparza Olaparib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Waymade-Trientine trientine hydrochloride Wilson's Disease Received
TBC lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Pending
Zevalin Ibritumomab tiuxetan CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Firazyr icatibant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed